On May 16, 2019, Huawei and 68 of its affiliates, including HiSilicon, were added to the U.S. Department of Commerce Entity List under U.S. Export Administration Regulations (the “EAR”). This action by the U.S. Department of Commerce imposed new export licensing requirements on exports, re-exports, and in-country transfers of all U.S. - regulated products, software and technology to the designated Huawei entities. On August 17, 2020, the U.S. Department of Commerce published final regulations expanding the scope of the U.S. EAR to include additional products that became subject to export restrictions relating to Huawei entities including HiSilicon. These new regulations restrict the sale to Huawei and the designated Huawei entities of certain non-U.S. made items, such as semiconductor devices, manufactured for or sold to Huawei entities including HiSilicon under specific, detailed conditions set forth in the new regulations. These new regulations have negatively impacted our sales to Huawei, HiSilicon and their suppliers. Teradyne is taking appropriate actions, including filing for licenses with the U.S. Department of Commerce. However, Teradyne cannot be certain that the actions it takes will mitigate the risks associated with the new export controls that impact its business. It is uncertain the extent these new regulations and any other additional regulations that may be implemented by the U.S. Department of Commerce or other government agency may have on Teradyne’s business and financial results.
On April 28, 2020, the U.S. Department of Commerce published new export control regulations for certain U.S. products and technology sold to military end users or for military end-use in China, Russia and Venezuela. The definition of military end user is broad. The regulations went into effect on June 29, 2020. In December 2020, the U.S. Department of Commerce issued a list of companies in China and other countries that it considered to be military end users. Teradyne does not expect that compliance with the new export controls will significantly impact its ability to sell products to its customers in China or to manufacture products in China. The new export controls, however, could disrupt the Company’s supply chain, increase compliance costs and impact the demand for the Company’s products in China and, thus, have a material adverse impact on Teradyne’s business, financial condition or results of operations. In addition, while the Company maintains an export compliance program, its compliance controls could be circumvented, exposing the Company to legal liabilities. Teradyne continues to assess the impact of the new export controls on its business and operations and take appropriate actions, including filing for licenses with the U.S. Department of Commerce, to minimize any disruption. However, Teradyne cannot be certain that the actions it takes will mitigate all the risks associated with the export controls that may impact its business.
In response to the regulations issued by the U.S. Department of Commerce, the Chinese government has passed new laws that may impact Teradyne’s business activities in China. The Company continues to assess the potential impact of these new Chinese laws and to monitor relevant laws and regulations issued by the Chinese government.
Following Russia’s invasion of Ukraine in February 2022, the U.S. and other countries imposed significant sanctions against the Russian government and many Russian companies and individuals. Although Teradyne does not have significant operations in Russia, the sanctions could impact Teradyne’s business in other countries and could have a negative impact on the Company’s supply chain, either of which could adversely affect Teradyne’s business and financial results.
COVID-19 has resulted in authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, government vaccination mandates and other government regulations. These measures have impacted and may further impact Teradyne’s workforce and operations, the operations of its customers, and those of its contract manufacturers and suppliers. As Teradyne implements measures to comply with additional regulations, the Company may experience increased compliance costs, increased risk of non-compliance and increased risk of employee attrition.
The COVID-19 pandemic has adversely impacted the Company’s results of operations, including increased costs company-wide and constraints within the Company’s supply chain. The Company cannot accurately estimate the amount of the impact on Teradyne’s 2022 financial results and to its future financial results. The COVID-19 outbreak has significantly increased economic and demand uncertainty in Teradyne’s markets. This uncertainty resulted in a significant decrease in demand for certain Teradyne products and could continue to impact demand for an uncertain period of time. The spread of COVID-19 has caused Teradyne to modify its business practices (including employee travel, employees working remotely, and cancellation of in person participation in meetings, events and conferences) and the Company may take further actions as may be required by government authorities or that it determines are in the best interests of its employees, customers, contract manufacturers and suppliers. There is uncertainty that such measures will be sufficient to mitigate the risks posed by the virus, and Teradyne’s ability to perform critical functions could be impacted. The degree to which COVID-19 continues to impact Teradyne’s results will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and continued spread of the virus, its severity, the actions to contain the virus or the availability and impact of vaccines in countries where the Company does business, and how quickly and to what extent normal economic and operating conditions can resume.
Important factors that could cause actual results, the 2024 earnings model, earnings per share, use of cash, dividend payments, repurchases of common stock, or payment of the senior convertible notes to differ materially from those presently expected include: conditions affecting the markets in which Teradyne operates; decreased or delayed product demand from one or more significant customers; development, delivery and acceptance of new products; the ability to grow the Industrial Automation business; increased research and development spending; deterioration of Teradyne’s financial condition; the continued impact of the COVID-19 pandemic and related government responses on the market and demand for Teradyne’s products, on its contract manufacturers and supply chain, and on its workforce; the impact of the global semiconductor supply shortage on our supply chain and contract manufacturers; the consummation and success of any mergers or acquisitions; demand for products by the Company’s largest customers; unexpected cash needs; insufficient cash flow to make required payments and pay the principal amount on the senior convertible notes; the business judgment of the board of directors that a declaration of a dividend or the repurchase of common stock is not in the Company’s best interests; additional U.S. tax regulations or IRS guidance; the impact of any tariffs or export controls imposed in the U.S. or China; compliance with trade protection measures or export restrictions; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei, HiSilicon and other customers or potential customers; sanctions imposed against the Russian government and certain Russian companies and individuals by the U.S., and other countries; and other events, factors and risks disclosed in filings with the SEC, including, but not limited to, the “Risk Factors” sections of Teradyne’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The forward-looking statements provided by Teradyne in this press release represent management’s views as of the date of this release. Teradyne anticipates that subsequent events and developments may cause management’s views to change. However, while Teradyne may elect to update these forward-looking statements at some point in the future, Teradyne specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Teradyne’s views as of any date subsequent to the date of this release.
TERADYNE, INC. REPORT FOR FIRST FISCAL QUARTER OF 2022 | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||
Quarter Ended | ||||||||||||||||
April 3,
2022 |
December 31,
2021 |
April 4,
2021 | ||||||||||||||
Net revenues | $ | 755,370 | $ | 885,047 | $ | 781,606 | ||||||||||
Cost of revenues (exclusive of acquired intangible assets amortization shown separately below) (1) | 300,437 | 357,998 | 319,988 | |||||||||||||
Gross profit | 454,933 | 527,049 | 461,618 | |||||||||||||
Operating expenses: | ||||||||||||||||
Selling and administrative | 140,185 | 142,747 | 129,797 | |||||||||||||
Engineering and development | 108,116 | 109,965 | 100,402 | |||||||||||||
Acquired intangible assets amortization | 5,063 | 5,163 | 5,536 | |||||||||||||
Restructuring and other (2) | 15,714 | 12,738 | (7,130 | ) | ||||||||||||
Operating expenses | 269,078 | 270,613 | 228,605 | |||||||||||||
Income from operations | 185,855 | 256,436 | 233,013 | |||||||||||||
Interest and other expense (3) | 5,496 | 1,256 | 9,020 | |||||||||||||
Income before income taxes | 180,359 | 255,180 | 223,993 | |||||||||||||
Income tax provision | 18,431 | 31,140 | 18,481 | |||||||||||||
Net income | $ | 161,928 | $ | 224,040 | $ | 205,512 | ||||||||||
Net income per common share: | ||||||||||||||||
Basic | $ | 1.00 | $ | 1.38 | $ | 1.23 | ||||||||||
Diluted | $ | 0.92 | $ | 1.26 | $ | 1.09 | ||||||||||
Weighted average common shares - basic | 162,048 | 162,769 | 166,491 | |||||||||||||
Weighted average common shares - diluted (4) | 175,565 | 178,020 | 187,740 | |||||||||||||
Cash dividend declared per common share | $ | 0.11 | $ | 0.10 | $ | 0.10 | ||||||||||
(1 | ) | Cost of revenues includes: | Quarter Ended | |||||||||||||
April 3,
2022 |
December 31,
2021 |
April 4,
2021 | ||||||||||||||
Provision for excess and obsolete inventory | $ | 1,590 | $ | 3,700 | $ | 2,827 | ||||||||||
Sale of previously written down inventory | (262 | ) | (434 | ) | (790 | ) | ||||||||||
$ | 1,328 | $ | 3,266 | $ | 2,037 | |||||||||||
(2 | ) | Restructuring and other consists of: | Quarter Ended | |||||||||||||
April 3,
2022 |
December 31,
2021 |
April 4,
2021 | ||||||||||||||
Litigation settlement | $ | 14,700 | $ | 12,000 | $ | - | ||||||||||
Employee severance | 551 | 284 | 188 | |||||||||||||
Acquisition related expenses and compensation | (201 | ) | 174 | (237 | ) | |||||||||||
Contingent consideration fair value adjustment | - | - | (7,227 | ) | ||||||||||||
Other | 664 | 280 | 146 | |||||||||||||
$ | 15,714 | $ | 12,738 | $ | (7,130 | ) | ||||||||||
(3 | ) | Interest and other includes: | Quarter Ended | |||||||||||||
April 3,
2022 |
December 31,
2021 |
April 4,
2021 | ||||||||||||||
Loss on convertible debt conversions | $ | - | $ | 3,431 | $ | 4,069 | ||||||||||
Non-cash convertible debt interest | - | 1,166 | 3,581 | |||||||||||||
Pension actuarial losses | - | (1,590 | ) | - | ||||||||||||
$ | - | $ | 3,007 | $ | 7,650 | |||||||||||
(4 | ) | Under GAAP, when calculating diluted earnings per share, convertible debt must be assumed to have converted if the effect on EPS would be dilutive. Diluted shares assume the conversion of the convertible debt as the effect would be dilutive. Accordingly, for the quarters ended April 3, 2022, December 31, 2021 and April 4, 2021, 2.5 million, 3.4 million and 10.3 million shares, respectively, have been included in diluted shares. For the quarters ended April 3, 2022, December 31, 2021 and April 4, 2021, diluted shares also included 10.0 million, 10.5 million and 9.4 million shares, respectively, from the convertible note hedge transaction. | ||||||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) | ||||||||||||||||
April 3,
2022 |
December 31,
2021 | |||||||||||||||
Assets | ||||||||||||||||
Cash and cash equivalents | $ | 794,603 | $ | 1,122,199 | ||||||||||||
Marketable securities | 282,016 | 244,231 | ||||||||||||||
Accounts receivable, net | 546,881 | 550,749 | ||||||||||||||
Inventories, net | 259,341 | 243,330 | ||||||||||||||
Prepayments | 479,414 | 406,266 | ||||||||||||||
Other current assets | 12,127 | 9,452 | ||||||||||||||
Total current assets | 2,374,382 | 2,576,227 | ||||||||||||||
Property, plant and equipment, net | 399,485 | 387,240 | ||||||||||||||
Operating lease right-of-use assets, net | 67,718 | 68,807 | ||||||||||||||
Marketable securities | 126,130 | 133,858 | ||||||||||||||
Deferred tax assets | 113,556 | 102,428 | ||||||||||||||
Retirement plans assets | 14,669 | 15,110 | ||||||||||||||
Other assets | 23,480 | 24,096 | ||||||||||||||
Acquired intangible assets, net | 69,846 | 75,635 | ||||||||||||||
Goodwill | 419,888 | 426,024 | ||||||||||||||
Total assets | $ | 3,609,154 | $ | 3,809,425 | ||||||||||||
Liabilities | ||||||||||||||||
Accounts payable | $ | 156,493 | $ | 153,133 | ||||||||||||
Accrued employees' compensation and withholdings | 139,287 | 253,667 | ||||||||||||||
Deferred revenue and customer advances | 155,761 | 146,185 | ||||||||||||||
Other accrued liabilities | 118,252 | 124,187 | ||||||||||||||
Operating lease liabilities | 18,523 | 19,977 | ||||||||||||||
Income taxes payable | 103,386 | 88,789 | ||||||||||||||
Current debt | 20,497 | 19,182 | ||||||||||||||
Total current liabilities | 712,199 | 805,120 | ||||||||||||||
Retirement plans liabilities | 151,697 | 151,141 | ||||||||||||||
Long-term deferred revenue and customer advances | 51,698 | 54,921 | ||||||||||||||
Long-term other accrued liabilities | 15,748 | 15,497 | ||||||||||||||
Deferred tax liabilities | 4,927 | 6,327 | ||||||||||||||
Long-term operating lease liabilities | 55,934 | 56,178 | ||||||||||||||
Long-term income taxes payable | 67,041 | 67,041 | ||||||||||||||
Debt | 75,378 | 89,244 | ||||||||||||||
Total liabilities | 1,134,622 | 1,245,469 | ||||||||||||||
Mezzanine equity | - | 1,512 | ||||||||||||||
Shareholders' equity | 2,474,532 | 2,562,444 | ||||||||||||||
Total liabilities, convertible common shares and shareholders’ equity | $ | 3,609,154 | $ | 3,809,425 | ||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) | ||||||||||||||||
Quarter Ended | ||||||||||||||||
April 3,
2022 |
April 4,
2021 | |||||||||||||||
Cash flows from operating activities: | ||||||||||||||||
Net income | $ | 161,928 | $ | 205,512 | ||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||
Depreciation | 22,503 | 23,910 | ||||||||||||||
Stock-based compensation | 12,894 | 12,232 | ||||||||||||||
Amortization | 5,233 | 9,822 | ||||||||||||||
Deferred taxes | 11,288 | (1,057 | ) | |||||||||||||
Losses (gains) on investments | 2,001 | (2,491 | ) | |||||||||||||
Provision for excess and obsolete inventory | 1,590 | 2,285 | ||||||||||||||
Loss on convertible debt conversions | - | 4,069 | ||||||||||||||
Contingent consideration fair value adjustment | - | (7,227 | ) | |||||||||||||
Other | 177 | 200 | ||||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||
Accounts receivable | 208 | (87,512 | ) | |||||||||||||
Inventories | (9,480 | ) | (35,870 | ) | ||||||||||||
Prepayments and other assets | (74,305 | ) | (86,131 | ) | ||||||||||||
Accounts payable and other liabilities | (124,382 | ) | (10,571 | ) | ||||||||||||
Deferred revenue and customer advances | 6,747 | 7,952 | ||||||||||||||
Retirement plans contributions | (1,329 | ) | (1,925 | ) | ||||||||||||
Income taxes | (7,611 | ) | 4,941 | |||||||||||||
Net cash provided by operating activities | 7,462 | 38,139 | ||||||||||||||
Cash flows from investing activities: | ||||||||||||||||
Purchases of property, plant and equipment | (43,999 | ) | (39,250 | ) | ||||||||||||
Purchases of marketable securities | (165,977 | ) | (211,604 | ) | ||||||||||||
Proceeds from maturities of marketable securities | 96,682 | 194,228 | ||||||||||||||
Proceeds from sales of marketable securities | 30,581 | 61,293 | ||||||||||||||
Net cash (used for) provided by investing activities | (82,713 | ) | 4,667 | |||||||||||||
Cash flows from financing activities: | ||||||||||||||||
Issuance of common stock under stock purchase and stock option plans | 16,475 | 17,144 | ||||||||||||||
Repurchase of common stock | (201,465 | ) | (45,188 | ) | ||||||||||||
Payments related to net settlement of employee stock compensation awards | (31,048 | ) | (30,675 | ) | ||||||||||||
Payments of convertible debt principal | (20,694 | ) | (51,275 | ) | ||||||||||||
Dividend payments | (17,895 | ) | (16,667 | ) | ||||||||||||
Net cash used for financing activities | (254,627 | ) | (126,661 | ) | ||||||||||||
Effects of exchange rate changes on cash and cash equivalents | 2,282 | 883 | ||||||||||||||
Decrease in cash and cash equivalents | (327,596 | ) | (82,972 | ) | ||||||||||||
Cash and cash equivalents at beginning of period | 1,122,199 | 914,121 | ||||||||||||||
Cash and cash equivalents at end of period | $ | 794,603 | $ | 831,149 | ||||||||||||